SMS Pharmaceuticals reported a consolidated profit after tax (PAT) of ₹20.91 crore for the first quarter ended June 30, 2026 (Q1FY27), marking an 8% year-on-year increase. The company’s revenue from operations rose 6% to ₹206.96 crore, supported by diversified growth in high-value active pharmaceutical ingredients (APIs). This performance underscores the effectiveness of its backward integration strategy and shift toward high-value therapeutic areas, which have improved unit economics despite stable EBITDA margins.

The financial results were approved by the Board of Directors in its meeting held on July 31, 2026, and reviewed by the Audit Committee. The Statutory Auditors carried out a limited review of the standalone and consolidated financial statements. The filing was submitted pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.

Financial Performance

Consolidated revenue from operations stood at ₹206.96 crore in Q1FY27, compared to ₹196.05 crore in the corresponding period of the previous year. Cost of goods sold (COGS) increased marginally by 2% to ₹132.03 crore, enabling gross profit to jump 12% to ₹74.93 crore. Consequently, gross margins expanded by 217 basis points to 36%, up from 34% in Q1FY26.

EBITDA grew 4% to ₹40.95 crore, maintaining a margin of 20%. Profit before tax (PBT) rose 12% to ₹27.20 crore, aided by a 195% surge in other income to ₹1.74 crore. After accounting for finance costs of ₹5.50 crore and taxes of ₹7.00 crore, net profit before share of associates was ₹20.20 crore. Including the share of associate profit, total consolidated PAT reached ₹20.91 crore.

Strategic Developments

SMS Pharmaceuticals is executing a ₹280 crore capital expenditure programme expected to be completed by FY27. This investment focuses on capacity expansion for existing APIs and building capabilities for new pipeline products. Additionally, the Board approved an infusion of up to ₹50 crore as a loan into its subsidiary, SMS Peptides Private Limited, to support its dedicated peptide R&D facility. This follows an earlier ₹8 crore investment made in FY26.

Geographically, North America accounted for 32% of sales. Therapeutically, Anti-Retro Viral (ARV) and Anti-inflammatory products emerged as the largest contributors, each accounting for 32% of the portfolio. The company also announced the completion of four DMF/CEP filings, putting it on track to meet its FY27 target of 10 filings.

What the Numbers Show

The divergence between stable EBITDA margins and expanding gross margins suggests operational leverage is being captured through product mix optimization rather than pure volume growth. With high-value products now constituting 51% of the portfolio (up from 30% in FY21), SMS Pharmaceuticals is successfully mitigating price erosion risks common in the generics landscape. However, the significant increase in other income warrants monitoring, as it contributed disproportionately to PBT growth compared to operational earnings.

SMS Pharmaceuticals reported a standalone net profit after tax (PAT) of ₹20.20 crore for the quarter ended June 30, 2026, marking an 8% year-on-year increase from ₹18.72 crore in Q1FY26. The growth was underpinned by a 6% rise in revenue from operations to ₹207.0 crore, driven by broad-based demand across high-value Active Pharmaceutical Ingredients (APIs). Consolidated PAT attributable to shareholders rose 2% to ₹20.91 crore, reflecting lower contributions from associate entities compared to the prior year. The company maintained a stable EBITDA margin of 20%, despite headwinds from annual employee increments and elevated freight costs due to geopolitical tensions in West Asia.

The financial performance highlights a strategic shift in the product portfolio, with Anti-Retro Viral (ARV) APIs emerging as a key growth driver. ARV revenues surged 69% year-on-year to ₹65.22 crore, accounting for 32% of total revenue, up from 20% in the previous year. Conversely, Anti-diabetic revenues declined 69% to ₹20.08 crore as the company deprioritized this segment. Gross profit expanded by 12% to ₹74.9 crore, with gross margins improving by 217 basis points to 36%, benefiting from backward integration and an optimized product mix. Executive Director P. Vamsi Krishna attributed the margin stability to structural improvements in unit economics, noting that temporary cost pressures are expected to ease in subsequent quarters.

Financial Performance Overview

The company’s total income stood at ₹208.71 crore, while operating expenses were managed effectively to sustain profitability. EBITDA increased 4% to ₹40.95 crore from ₹39.37 crore in Q1FY26. The divergence between consolidated and standalone profit growth is primarily due to the share of profit from associate VKT Pharma Private Limited, which dropped significantly to ₹0.71 crore from ₹1.78 crore in the corresponding period of FY26. This reduction impacted the consolidated bottom line more than the standalone figures.

Strategic Developments and Capex Progress

SMS Pharmaceuticals is advancing its ₹280 crore capital expenditure programme, with ₹120 crore already completed. The remaining ₹160 crore is expected to be finalized by FY27, supporting the commercialization of new niche molecules. In parallel, the Board approved an unsecured loan of up to ₹50 crore to its subsidiary, SMS Peptides Private Limited, building on a previous ₹8 crore investment in FY26 to establish a dedicated peptide R&D facility. This infusion aims to strengthen the company’s position in the complex peptide CDMO space.

On the research front, the company completed four Drug Master File (DMF) and Certificate of Suitability (CEP) filings during the quarter, keeping it on track to meet its FY27 target of ten filings. The R&D team has expanded to 200 members, developing a pipeline of six to eight niche high-value molecules expected to enter commercial production later in FY27. Management projects that volume growth in Ibuprofen and expanding contributions from high-value APIs will further support revenue momentum in the coming quarters.

What the Numbers Show

The significant swing in therapeutic area contributions underscores SMS Pharma’s successful portfolio diversification. The 69% surge in ARV revenues offset the sharp decline in anti-diabetic sales, indicating a deliberate strategic pivot toward higher-margin, regulated market products. While gross margins improved substantially due to backward integration, the flat EBITDA margin suggests that operational efficiencies are currently being absorbed by increased manpower costs and external freight pressures. Investors should monitor whether these temporary headwinds recede in Q2FY27, potentially unlocking margin expansion alongside the anticipated volume growth from new capacity additions.